Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Issues Earnings Results

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) released its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, FiscalAI reports.

Calidi Biotherapeutics Price Performance

Shares of NYSEAMERICAN:CLDI traded down $0.00 on Friday, hitting $0.19. The company’s stock had a trading volume of 3,471,379 shares, compared to its average volume of 10,530,117. The company has a 50-day simple moving average of $0.27 and a 200 day simple moving average of $0.87. Calidi Biotherapeutics has a 1 year low of $0.16 and a 1 year high of $19.20. The company has a market capitalization of $2.02 million, a PE ratio of -0.04 and a beta of 1.38. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.59 and a quick ratio of 1.59.

Institutional Trading of Calidi Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of CLDI. Warberg Asset Management LLC purchased a new stake in shares of Calidi Biotherapeutics in the 3rd quarter valued at about $28,000. Geode Capital Management LLC raised its holdings in shares of Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares in the last quarter. DRW Securities LLC purchased a new stake in shares of Calidi Biotherapeutics in the 4th quarter valued at about $173,000. Finally, Virtu Financial LLC purchased a new stake in shares of Calidi Biotherapeutics in the 4th quarter valued at about $25,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.